Cytotoxicity of activated natural killer cells against pediatric solid tumors. - Wikidata - awgldk - TriplyDB

Cytotoxicity of activated natural killer cells against pediatric solid tumors.

Cytotoxicity of activated natural killer cells against pediatric solid tumors.

http://www.wikidata.org/entity/Q30503995

about

Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress Immunotherapy of Childhood Sarcomas Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches Adoptive cell therapy for sarcoma Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells A Novel Method for Assessment of Natural Killer Cell Cytotoxicity Using Image Cytometry Natural killer cells in human cancer: from biological functions to clinical applications Potential approaches to the treatment of Ewing's sarcoma "Adherent" versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer Immunotherapy Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells New strategies in ewing sarcoma: lost in translation?Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection.Targeted Therapy of Ewing's Sarcoma.Current therapeutic approaches in metastatic and recurrent ewing sarcoma Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells.NK cell-based immunotherapy for treating cancer: will it be promising?Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells.Prolonged overall survival in gastric cancer patients after adoptive immunotherapy DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma.Neuroblastoma: developmental biology, cancer genomics and immunotherapy.3D tissue-engineered model of Ewing's sarcoma Natural killer cell engineering for cellular therapy of cancer Cell docking, movement and cell-cell interactions of heterogeneous cell suspensions in a cell manipulation microdevice.NK cell-based immunotherapies in Pediatric Oncology.Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor.The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours.Efficient Killing of High Risk Neuroblastoma Using Natural Killer Cells Activated by Plasmacytoid Dendritic Cells.Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.Strategies and developments of immunotherapies in osteosarcoma A proposed role for neutrophil extracellular traps in cancer immunoediting.IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production.Immunotherapy in pediatric malignancies: current status and future perspectives

P2860

Q26781260-E70A63C1-E4C4-49EB-95AE-47A97A6C732E Q26795369-02E9D57C-2434-4F40-8430-513BCAF331EC Q26801785-4EA6E093-A96C-44A3-859A-76B75EBA0C40 Q26825652-21029915-4B48-4E39-AA49-88FA1E2885C0 Q27009541-2FA932FC-C54B-4508-862E-9D97E7C1208C Q27309991-47B3578B-ACC3-46D2-BC54-49F3479758C3 Q27312227-411D9037-9C2D-42AF-A797-A6F8D02C19D7 Q27691427-4A003908-8D4A-4F94-8C2A-357CAE4D3ED8 Q28072744-AC4BE395-E3F1-4FCA-ABF2-F4ED7F2C6FC1 Q28081338-D97660FC-7397-4F9C-A57D-2363D2B4E810 Q30916013-18FCB919-B4F1-4F8D-AF76-AAA292E9C2C5 Q33584049-F4FBC3CF-C28D-4EB8-AEBA-B28C451FD98F Q33758471-92B25A2E-E26C-4ECF-9A29-45981FC3E2EE Q34166288-FF843CB4-F12F-4097-ADB0-DDAEC5E6B6FA Q34262377-83B513B1-7141-42D3-8615-451A76FB37DB Q34373180-C32624C2-6056-44B5-833B-E0451398E7C2 Q34700290-7B14ADB0-064C-472E-AF0A-1BE29E38A77E Q34729280-FEA47686-7D3A-4726-943E-994F7975AA4B Q34786566-CC1C69E0-E989-4DE5-BD69-E637415C1A56 Q35022931-9B3C18F3-BB51-41CF-AF16-380001F88E44 Q35029441-9BE99A12-6768-4A08-B8B6-EE97A9D09CB6 Q35083496-C5AA560C-BEA1-4B48-ACB2-6725D8E6D57F Q35152386-7F37506A-B296-417D-A3FE-19971D2FB2E1 Q35209066-20EA6C88-4164-4601-B265-1F96FDCA75DA Q35283020-1F51AAD1-7FE2-413C-AA4F-A6041EAB8418 Q35428655-2F63413E-717F-4078-8F4D-D750AB2C4C66 Q35556865-1533B1F1-532C-4B2C-963F-DA3282A5DCB2 Q35594202-33A2384B-9EB1-4B64-BB56-E150A11D2B6E Q35600975-5B8504DF-4AC9-4A41-BD5F-A218D8891F84 Q35634680-2373AB93-C19F-49CB-8BBD-55D496D6EA8F Q35721147-36FD1FC8-0B43-4F9D-9E7F-CCEE1CC2824E Q35832365-E5375696-7DF9-4B09-9929-3B550A2355A3 Q35957998-13CBA9C3-9400-4913-ACD5-A325CA145188 Q36157777-C61E8F44-CB2E-4889-A3E8-3001F343A92A Q36212437-5EEF93F6-FA58-40A4-BDEF-CFA00200244E Q36261159-44933D2D-F851-4705-B67E-8CAC7159F318 Q36503128-CF2D6211-934E-46B5-8EC1-CE14DFF53914 Q36660838-8D4CF877-4D18-44A6-BA47-9D5D973FF7CE Q36671364-EAC942F5-1B49-4DA9-9E89-987837C6BF2F Q36691818-263379C6-E17E-4D68-80F0-5AA8A9EFCFA5

P2860

Cytotoxicity of activated natural killer cells against pediatric solid tumors.

http://www.wikidata.org/entity/Q30503995

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Cytotoxicity of activated natural killer cells against pediatric solid tumors.

@ast

Cytotoxicity of activated natural killer cells against pediatric solid tumors.

@en

type

label

Cytotoxicity of activated natural killer cells against pediatric solid tumors.

@ast

Cytotoxicity of activated natural killer cells against pediatric solid tumors.

@en

prefLabel

Cytotoxicity of activated natural killer cells against pediatric solid tumors.

@ast

Cytotoxicity of activated natural killer cells against pediatric solid tumors.

@en

P1433

Q30503995-7E793EE0-07B7-45F0-8565-4B5FFC0C8479

P1476

Q30503995-5BEBCE1D-4B1E-4241-BAFC-BD93324C7B7E

P2093

Q30503995-71358E5D-E3A4-4CCB-BFC2-28EBFC4BBB8A

Q30503995-86810337-6307-4815-99CB-C30332EC9FAB

Q30503995-BA08D5C4-F6CA-43E7-B4A9-7E2427F06C5F

Q30503995-BEA29F54-2524-47E9-94EF-2C4F06D4A966

Q30503995-D34ECD97-5DEF-4D40-A8A4-90B26EEA4C9B

Q30503995-F29093C6-C5FB-4852-8C94-3ECCC1866346

P2860

Q30503995-0561ECFD-AFB6-4ABF-AE1F-D700706E90E0

Q30503995-0EE685B2-7861-4AD6-A9C4-26389A1393D3

Q30503995-1500AAFB-4294-45D0-A0FF-9D18463CE58C

Q30503995-189E9CB9-6F1A-4111-86D3-60029C5BCB57

Q30503995-224CA269-6CF3-496A-9B4A-F962A3A504C9

Q30503995-2C8BD6C7-5A3F-4BB1-B97B-37FDBEB4D538

Q30503995-2CFF8762-3D3A-407A-AA7C-C84046809E51

Q30503995-3B66DF10-92F7-462A-BA85-A6A4F002C179

Q30503995-3C4C6639-26E3-4AFA-AED6-0B08158C5FC2

Q30503995-3F40B868-956D-4504-8D24-11ACCA195D54

P304

Q30503995-45C4F3AF-12E8-4F74-9C58-6BE543390C24

P31

Q30503995-4C52C111-DCC4-4474-9642-E71DD7356725

P356

Q30503995-9D1EA5D8-51BB-4EC1-9391-ED48939D585F

P407

Q30503995-EE37EB19-2415-4A34-A183-D477C507FE79

P433

Q30503995-30CD92AB-72DE-424B-B95D-DFB890A477C9

P478

Q30503995-037A3DA2-76C1-4758-A0FC-435C82DE2B68

P577

Q30503995-131CB401-1238-485E-81FD-70D0CC6316F7

P698

Q30503995-36FF85CE-AA69-4DB5-B2F8-5276D9AA8C68

P921

Q30503995-A2641847-A5CD-448C-AC07-36B421F6DD54

P932

Q30503995-885557DF-0EFD-4E14-BED8-6D3EDFA68C75

P356

1078-0432.CCR-10-0735

P1433

Clinical Cancer Research

P1476

Cytotoxicity of activated natural killer cells against pediatric solid tumors.

@en

P2093

Dario Campana

http://www.w3.org/2001/XMLSchema#string

David R Shook

http://www.w3.org/2001/XMLSchema#string

Duck Cho

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Fujisaki

http://www.w3.org/2001/XMLSchema#string

Noriko Shimasaki

http://www.w3.org/2001/XMLSchema#string

Yu-Hsiang Chang

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture

ERG gene is translocated in an Ewing's sarcoma cell line

NK cell recognition

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group

NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.

Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells.

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.

P304

3901-3909

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-0735

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20542985

http://www.w3.org/2001/XMLSchema#string

P921

P932

3168562

http://www.w3.org/2001/XMLSchema#string